Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of paclitaxel plus estramustine in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.
|Prostate Cancer||Drug: estramustine phosphate sodium Drug: paclitaxel||Phase 2|
|Study Design:||Primary Purpose: Treatment|
|Official Title:||Phase II Study of Weekly Paclitaxel by 1-HR Infusion Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma|
|Study Start Date:||December 1998|
|Primary Completion Date:||April 2005 (Final data collection date for primary outcome measure)|
OBJECTIVES: I. Determine the effect of weekly paclitaxel plus estramustine on PSA response in patients with metastatic hormone-refractory prostate cancer. II. Describe the toxic effects of this treatment in this patient population. III. Determine the effect of treatment on pain, asthenia, and quality of life. IV. Determine the objective response rate after treatment among the patients with bidimensionally measurable disease.
OUTLINE: Patients receive estramustine orally twice a day on days 1-3 of each week for 6 weeks. Patients also receive paclitaxel IV over 1 hour on day 2 of each week for 6 weeks. Courses repeat every 8 weeks in the absence of unacceptable toxicity and disease progression. Quality of life is assessed prior to treatment and at weeks 4, 8, 20, and 24. Patients are followed every 3 months for 2 years, every 6 months for years 2-5, and then annually thereafter.
PROJECTED ACCRUAL: There will be 17-52 patients accrued into this study over 14 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00003614
Show 28 Study Locations
|Study Chair:||Gary R. Hudes, MD||Fox Chase Cancer Center|